Schrodinger (SDGR) Company Report

Schrödinger reported $54 million in revenue for the recently concluded quarter, representing 54% year-on-year growth, with $40.9 million from software and $13.5 million from drug discovery.
The company maintained its total revenue guidance at $250 million, but adjusted its outlook to a slight decrease in software revenue (8%-13%) offset by a slight increase in drug discovery revenue ($49-$52 million).
Schrödinger announced a strategic shift to an R&D-based model, intending to complete dose escalation studies on its two clinical programs (3515 and 1505) and then seek partners for further development, aiming to become a more focused and streamlined company with a goal towards profitability.
The company holds $401 million in cash and has implemented expense reduction programs, including a $30 million program in May and an estimated $40 million saving from transferring clinical programs, which is expected to improve its operational and profitability profile and extend its cash runway.
Schrödinger has generated $600 million in the last five years through upfronts, company sales, and milestones from preclinical discovery partnerships, with 15 programs entitling them to milestones or royalties, representing a collective milestone opportunity of $5 billion.

Nov 19, 2025, 4:00 PM

Transcript

Schrödinger Reports Quarterly Revenue and Announces Strategic Shift

SDGR

Guidance Update

New Projects/Investments

Revenue Acceleration/Inflection

Schrödinger reported $54 million in revenue for the quarter, representing a 54% year-over-year increase, with software revenue at $40.9 million (up 28%) and drug discovery revenue at $13.5 million.
The company maintained its total revenue guidance of approximately $250 million for the year, but adjusted software revenue guidance to 8%-13% and drug discovery revenue guidance to $49-$52 million, indicating a slight decrease in software revenue offset by an increase in drug discovery.
Schrödinger announced a strategic shift to an R&D-based model, focusing on completing dose escalation studies for its two clinical programs (3515 and 1505) and then seeking partners for further development, while no longer advancing internal assets to the IND stage. This change is expected to result in approximately $40 million in savings and aims for a more focused, streamlined, and profitable company.
The company ended the quarter with $401 million in cash and implemented a $30 million expense reduction program in May, with more than half to be recognized in 2025.

Nov 19, 2025, 4:00 PM

Transcript

Schrödinger Provides Business Update and Strategic Shift Details at Jefferies Conference

SDGR

Guidance Update

New Projects/Investments

M&A

Schrödinger reported $54 million in revenue for the quarter, representing 54% year-on-year growth, with software revenue at $40.9 million (up 28%) and drug discovery revenue at $13.5 million. The company maintains its total revenue guidance of approximately $250 million for the year, with software revenue guidance of 8%-13% and drug discovery revenue guidance of $49-$52 million.
The company is implementing a strategic shift to focus on an R&D-based discovery model, intending to complete dose escalation studies for its two clinical programs (MALT1 and Wee1/Myt1) and then seek partners for further development, rather than advancing internal assets to the IND stage. This move is intended to create a more focused, streamlined, and profitable company.
Schrödinger ended the quarter with $401 million in cash and has initiated cost optimization efforts, including a $30 million expense reduction program and an anticipated $40 million saving from partnering clinical programs, which are expected to improve its operational and profitability profile and extend its cash runway. The company highlighted its success in preclinical drug discovery, having generated $600 million in the last five years from discovery partnerships, with 15 programs offering a collective $5 billion in milestone opportunities.

Nov 19, 2025, 4:00 PM

Transcript

Schrödinger Reports Q3 2025 Results and Updates 2025 Guidance

SDGR

Earnings

Guidance Update

Demand Weakening

Schrödinger reported total revenue of $54.3 million for Q3 2025, marking a 54% increase compared to Q3 2024, driven by $40.9 million in software revenue (up 28%) and $13.5 million in drug discovery revenue.
The company recorded a net loss of $33 million, or $0.45 per diluted share, for Q3 2025, and maintained a strong financial position with $401 million in cash and equivalents as of September 30.
Schr\u00f6dinger updated its full-year 2025 software revenue growth guidance to 8%-13% (from 10%-15%) due to delays in pharma scale-up opportunities, while simultaneously increasing its drug discovery revenue guidance to $49-$52 million (from $45-$50 million).
The company announced a strategic decision to no longer advance internal discovery programs into the clinic independently, a move that, combined with a $30 million expense reduction in May, is expected to result in approximately $70 million in total savings and enhance long-term profitability.

Nov 5, 2025, 9:30 PM

Transcript

Schrödinger Announces Q3 2025 Financial Results and Updates 2025 Guidance

SDGR

Earnings

Guidance Update

New Projects/Investments

Schrödinger reported strong Q3 2025 total revenue of $54.3 million, marking a 54% increase year-over-year, driven by 28% growth in software revenue to $40.9 million and $13.5 million in drug discovery revenue.
The company's net loss improved to $32.8 million in Q3 2025 from $38.1 million in Q3 2024, with operating expenses decreasing 14% to $74.0 million.
For fiscal year 2025, Schrödinger updated its guidance, projecting software revenue growth of 8%-13% and drug discovery revenue between $49 million and $52 million, alongside an expected reduction in operating expenses and cash used in operating activities compared to 2024.
Strategically, the company is phasing out independent clinical development activities and exploring partnering opportunities for its therapeutics portfolio, with initial Phase 1 data for SGR-3515 anticipated in 1H 2026.

Nov 5, 2025, 9:30 PM

Presentation

Schr\u00f6dinger Reports Third Quarter 2025 Financial Results and Updates 2025 Guidance

SDGR

Earnings

Guidance Update

Demand Weakening

Schr\u00f6dinger reported total revenue of $54.3 million for the third quarter of 2025, representing a 54% increase compared to the third quarter of 2024, with software revenue growing 28% to $40.9 million and drug discovery revenue reaching $13.5 million.
The company's net loss for Q3 2025 was $32.8 million, an improvement from a $38.1 million net loss in Q3 2024, primarily due to a decrease in operating expenses to $74.0 million from $86.2 million in the prior year period.
Schr\u00f6dinger updated its 2025 full-year guidance, lowering software revenue growth expectations to 8% to 13% (from a prior expectation of 10% to 15%) but increasing drug discovery revenue expectations to $49 million to $52 million (from $45 million to $50 million).
The company announced a shift towards a discovery-focused therapeutics R&D model, intending not to advance discovery programs into the clinic independently beyond existing commitments, and expects approximately $70 million in savings from this and earlier expense-reduction measures.

Nov 5, 2025, 9:09 PM

8-K

Schrödinger Reports Third Quarter 2025 Financial Results and Updates 2025 Guidance

SDGR

Earnings

Guidance Update

New Projects/Investments

Schrödinger reported total revenue of $54.3 million for the third quarter of 2025, marking a 54% increase compared to the third quarter of 2024. Software revenue grew 28% to $40.9 million, and drug discovery revenue increased 295% to $13.5 million.
The company updated its 2025 financial guidance, lowering expected software revenue growth to a range of 8% to 13% (from 10% to 15%) but increasing drug discovery revenue guidance to $49 million to $52 million (from $45 million to $50 million).
Schrödinger announced a strategic shift towards a discovery-focused therapeutics R&D model, anticipating approximately $70 million in savings from expense-reduction measures and stating it does not intend to advance discovery programs into the clinic independently beyond SGR-1505 and SGR-3515.
The net loss for the third quarter of 2025 was $32.8 million, an improvement from a $38.1 million net loss in the third quarter of 2024. The company held $401.0 million in cash, cash equivalents, restricted cash, and marketable securities at the end of the quarter.

Nov 5, 2025, 9:05 PM

Press Release

Schrödinger and Copernic Catalysts Achieve Ammonia Catalyst Milestone

SDGR

New Projects/Investments

Product Launch

Schrödinger, in collaboration with Copernic Catalysts, has surpassed the final technical milestone for their jointly-developed Neptune™ ammonia synthesis catalyst, which demonstrated an ammonia yield over two times higher than competing catalysts.
The Neptune catalyst has the potential to increase industrial ammonia plant capacity by up to 47 percent, translating to up to $110 million in additional annual profits per plant and up to a 23 percent reduction in energy consumption.
Building on this success, the companies have initiated work on their next joint project, designing a selective ethylene oxide (EO) catalyst.
This achievement highlights the effectiveness of Schrödinger's advanced simulation methods when combined with experimental approaches in materials design.

Oct 30, 2025, 11:30 AM

Press Release

Schrodinger Inc reports results of 2025 Annual Meeting of Stockholders

SDGR

Proxy Vote Outcomes

Quorum established with 52,556,775 common shares and 9,164,193 limited shares; four Class II directors elected, advisory vote on executive compensation approved, and KPMG LLP ratified as independent auditor.
CEO Rami Farid highlighted 1,800 customers and the hybrid physics–machine learning computational platform driving drug and materials discovery.
Announced Phase 1 data for SGR1505 in advanced relapsed/refractory B cell malignancies showing favorable safety and preliminary efficacy, with FDA discussions on the recommended Phase 2 dose planned later in 2025.
Confirmed upcoming H2 2025 data presentations for SGR2921 (CDC7 inhibitor in AML/MDS) and SGR3515 (advanced solid tumors), alongside continued platform enhancements and collaboration expansions.

Jun 18, 2025, 4:41 PM

Schrodinger presents Phase I data for MALT1 inhibitor SGR1505 at EHA

SDGR

Reviewed Phase I data in 49 heavily pretreated relapsed/refractory B-cell malignancy patients; no dose-limiting toxicities observed and a favorable safety profile with 43% experiencing treatment-related AEs; asymptomatic bilirubin increases occurred in patients with UGT1A1 polymorphisms.
Pharmacodynamics confirmed ≈90% inhibition of T-cell derived IL-2 at steady state for doses ≥150 mg QD and all BID regimens, with more sustained suppression on the BID schedule.
Among 45 efficacy-evaluable patients, the overall response rate was 22%, including responses in 3/17 CLL, 5/5 Waldenström’s macroglobulinemia, 1/5 marginal zone lymphoma and 1/4 ABC-DLBCL; one Waldenström’s patient remains on treatment for nearly two years.
Dose escalation is complete (300 mg QD and 150 mg BID); next steps include an FDA meeting to set the Phase II recommended dose and plans to explore combinations with BTK and BCL2 inhibitors.

Jun 12, 2025, 1:31 PM

Earnings Transcripts

Quarterly earnings call transcripts for Schrodinger.

Ask Fintool AI Agent

Get instant answers from SEC filings, earnings calls & more

What did Ramy Farid say about margins?What are Schrodinger's strategic priorities?How is Schrodinger positioned vs competitors?How did Schrodinger do last quarter?

Let Fintool AI Agent track Schrodinger's earnings for you

Get instant analysis when filings drop